Literature DB >> 21491613

Glyoxalase I polymorphism rs2736654 causing the Ala111Glu substitution modulates enzyme activity--implications for autism.

Madhabi Barua1, Edmund C Jenkins, Wenqiang Chen, Salomon Kuizon, Raju K Pullarkat, Mohammed A Junaid.   

Abstract

Autism is a pervasive, heterogeneous, neurodevelopmental disability characterized by impairments in verbal communications, reciprocal social interactions, and restricted repetitive stereotyped behaviors. Evidence suggests the involvement of multiple genetic factors in the etiology of autism, and extensive genome-wide association studies have revealed several candidate genes that bear single nucleotide polymorphisms (SNPs) in non-coding and coding regions. We have shown that a non-conservative, non-synonymous SNP in the glyoxalase I gene, GLOI, may be an autism susceptibility factor. The GLOI rs2736654 SNP is a C→A change that causes an Ala111Glu change in the Glo1 enzyme. To identify the significance of the SNP, we have conducted functional assays for Glo1. We now present evidence that the presence of the A-allele at rs2736654 results in reduced enzyme activity. Glo1 activity is decreased in lymphoblastoid cells that are homozygous for the A allele. The Glu-isoform of Glo1 in these cells is hyperphosphorylated. Direct HPLC measurements of the glyoxalase I substrate, methylglyoxal (MG), show an increase in MG in these cells. Western blot analysis revealed elevated levels of the receptor for advanced glycation end products (RAGEs). We also show that MG is toxic to the developing neuronal cells. We suggest that accumulation of MG results in the formation of AGEs, which induce expression of the RAGE that during crucial neuronal development may be a factor in the pathology of autism.
Copyright © 2011, International Society for Autism Research, Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21491613      PMCID: PMC3138858          DOI: 10.1002/aur.197

Source DB:  PubMed          Journal:  Autism Res        ISSN: 1939-3806            Impact factor:   5.216


  54 in total

1.  Sequence and structure-based prediction of eukaryotic protein phosphorylation sites.

Authors:  N Blom; S Gammeltoft; S Brunak
Journal:  J Mol Biol       Date:  1999-12-17       Impact factor: 5.469

Review 2.  Autism spectrum disorders.

Authors:  C Lord; E H Cook; B L Leventhal; D G Amaral
Journal:  Neuron       Date:  2000-11       Impact factor: 17.173

3.  The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells.

Authors:  N Tanaka; H Yonekura; S Yamagishi; H Fujimori; Y Yamamoto; H Yamamoto
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

4.  Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE.

Authors:  Franky Van Herreweghe; Jianqiang Mao; Frank W R Chaplen; Johan Grooten; Kris Gevaert; Joël Vandekerckhove; Katia Vancompernolle
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

5.  Neurotoxicity of advanced glycation end-products for cultured cortical neurons.

Authors:  M Takeuchi; R Bucala; T Suzuki; T Ohkubo; M Yamazaki; T Koike; Y Kameda; Z Makita
Journal:  J Neuropathol Exp Neurol       Date:  2000-12       Impact factor: 3.685

6.  Increased serum levels of high mobility group box 1 protein in patients with autistic disorder.

Authors:  Enzo Emanuele; Marianna Boso; Natascia Brondino; Stefania Pietra; Francesco Barale; Stefania Ucelli di Nemi; Pierluigi Politi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-03-17       Impact factor: 5.067

7.  Minicolumnar pathology in autism.

Authors:  Manuel F Casanova; Daniel P Buxhoeveden; Andrew E Switala; Emil Roy
Journal:  Neurology       Date:  2002-02-12       Impact factor: 9.910

Review 8.  Epilepsy in autism.

Authors:  Roberto Tuchman; Isabelle Rapin
Journal:  Lancet Neurol       Date:  2002-10       Impact factor: 44.182

9.  Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification.

Authors:  Hiroshi Sakamoto; Tetsuo Mashima; Kazuo Yamamoto; Takashi Tsuruo
Journal:  J Biol Chem       Date:  2002-09-10       Impact factor: 5.157

10.  Evidence of brain overgrowth in the first year of life in autism.

Authors:  Eric Courchesne; Ruth Carper; Natacha Akshoomoff
Journal:  JAMA       Date:  2003-07-16       Impact factor: 56.272

View more
  18 in total

Review 1.  Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.

Authors:  Megan Jack; Douglas Wright
Journal:  Transl Res       Date:  2012-01-10       Impact factor: 7.012

2.  Mitochondria, Metabolism, and Redox Mechanisms in Psychiatric Disorders.

Authors:  Yeni Kim; Krishna C Vadodaria; Zsolt Lenkei; Tadafumi Kato; Fred H Gage; Maria C Marchetto; Renata Santos
Journal:  Antioxid Redox Signal       Date:  2019-02-01       Impact factor: 8.401

3.  Polymorphisms of the receptor for advanced glycation end-products and glyoxalase I in patients with renal cancer.

Authors:  Matúš Chocholatý; Marie Jáchymová; Marek Schmidt; Klára Havlová; Anna Křepelová; Tomáš Zima; Marko Babjuk; Marta Kalousová
Journal:  Tumour Biol       Date:  2014-11-19

4.  Weak association of glyoxalase 1 (GLO1) variants with autism spectrum disorder.

Authors:  Jernej Kovač; Katarina Trebušak Podkrajšek; Marta Macedoni Lukšič; Tadej Battelino
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-03-27       Impact factor: 4.785

5.  Transcriptome study of differential expression in schizophrenia.

Authors:  Alan R Sanders; Harald H H Göring; Jubao Duan; Eugene I Drigalenko; Winton Moy; Jessica Freda; Deli He; Jianxin Shi; Pablo V Gejman
Journal:  Hum Mol Genet       Date:  2013-07-30       Impact factor: 6.150

Review 6.  High-mobility group box 1 (HMGB1) in childhood: from bench to bedside.

Authors:  Valeria Chirico; Antonio Lacquaniti; Vincenzo Salpietro; Caterina Munafò; Maria Pia Calabrò; Michele Buemi; Teresa Arrigo; Carmelo Salpietro
Journal:  Eur J Pediatr       Date:  2014-05-09       Impact factor: 3.183

7.  Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal.

Authors:  Margaret G Distler; Leigh D Plant; Greta Sokoloff; Andrew J Hawk; Ivy Aneas; Gerald E Wuenschell; John Termini; Stephen C Meredith; Marcelo A Nobrega; Abraham A Palmer
Journal:  J Clin Invest       Date:  2012-05-15       Impact factor: 14.808

8.  Glyoxalase 1-419C>A variant is associated with oxidative stress: implications in prostate cancer progression.

Authors:  Cinzia Antognelli; Letizia Mezzasoma; Ettore Mearini; Vincenzo Nicola Talesa
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

9.  Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights.

Authors:  Margaret G Distler; Abraham A Palmer
Journal:  Front Genet       Date:  2012-11-19       Impact factor: 4.599

10.  Association of oxidative stress to the genesis of anxiety: implications for possible therapeutic interventions.

Authors:  Waseem Hassan; Carlos Eduardo Barroso Silva; Imdad Ullah Mohammadzai; Joao Batista Teixeira da Rocha; Landeira-Fernandez J
Journal:  Curr Neuropharmacol       Date:  2014-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.